entinostat has been researched along with Cancer of Ovary in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "There is an immunoreactive subtype of ovarian cancer with a favorable prognosis, but the majority of ovarian cancers have limited immune reactivity." | 1.62 | Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition. ( Anderson, L; Chen, HW; Fejzo, MS; Karlan, B; Konecny, GE; McDermott, MS; Slamon, DJ, 2021) |
| "Entinostat was synergistic with cisplatin in all cell lines in MTT and caspase activation assays." | 1.51 | Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines. ( Bandolik, JJ; Hamacher, A; Kassack, MU; Schrenk, C; Weishaupt, R, 2019) |
| "Entinostat treatment decreased the growth of both subcutaneously and omental ID8 tumors and prolonged survival in immunocompetent C57BL/6 mice." | 1.48 | The antitumor effects of entinostat in ovarian cancer require adaptive immunity. ( Arend, RC; Buchsbaum, DJ; Forero, A; Katre, AA; Londono, AI; McCaw, TR; Meza-Perez, S; Norian, LA; Randall, TD; Smith, HJ; Straughn, JM; Yang, ES, 2018) |
| "Treatment with entinostat and azacytidine of ID8 cells in vitro increased mRNA levels of Cd74, Ciita, and H2-Aa, H2-Eb1." | 1.46 | Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth. ( Arend, RC; Buchsbaum, DJ; Forero, A; Katre, A; Londoño, A; Meza-Perez, S; Norian, LA; Peabody, JE; Randall, TD; Smith, HJ; Straughn, JM; Turner, TB, 2017) |
| "Women with ovarian cancer may be at increased risk for psychological distress around the time of diagnosis relative to patients diagnosed with other cancers, because of the seriousness of the disease." | 1.38 | Bioinformatics analysis reveals potential candidate drugs for psychological stress in ovarian cancer. ( Li, W; Sun, N; Zang, W, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Krieger, V | 1 |
| Hamacher, A | 2 |
| Cao, F | 1 |
| Stenzel, K | 1 |
| Gertzen, CGW | 1 |
| Schäker-Hübner, L | 1 |
| Kurz, T | 1 |
| Gohlke, H | 1 |
| Dekker, FJ | 1 |
| Kassack, MU | 2 |
| Hansen, FK | 1 |
| Fejzo, MS | 1 |
| Chen, HW | 1 |
| Anderson, L | 1 |
| McDermott, MS | 1 |
| Karlan, B | 1 |
| Konecny, GE | 1 |
| Slamon, DJ | 1 |
| Gupta, VG | 1 |
| Hirst, J | 1 |
| Petersen, S | 1 |
| Roby, KF | 1 |
| Kusch, M | 1 |
| Zhou, H | 1 |
| Clive, ML | 1 |
| Jewell, A | 1 |
| Pathak, HB | 1 |
| Godwin, AK | 1 |
| Wilson, AJ | 1 |
| Crispens, MA | 1 |
| Cybulla, E | 1 |
| Vindigni, A | 1 |
| Fuh, KC | 1 |
| Khabele, D | 1 |
| Turner, TB | 1 |
| Meza-Perez, S | 2 |
| Londoño, A | 1 |
| Katre, A | 1 |
| Peabody, JE | 1 |
| Smith, HJ | 2 |
| Forero, A | 2 |
| Norian, LA | 2 |
| Straughn, JM | 2 |
| Buchsbaum, DJ | 2 |
| Randall, TD | 2 |
| Arend, RC | 2 |
| McCaw, TR | 1 |
| Londono, AI | 1 |
| Katre, AA | 1 |
| Yang, ES | 1 |
| Surolia, I | 1 |
| Bates, SE | 1 |
| Bandolik, JJ | 1 |
| Schrenk, C | 1 |
| Weishaupt, R | 1 |
| Sun, N | 1 |
| Zang, W | 1 |
| Li, W | 1 |
| Saito, A | 1 |
| Yamashita, T | 1 |
| Mariko, Y | 1 |
| Nosaka, Y | 1 |
| Tsuchiya, K | 1 |
| Ando, T | 1 |
| Suzuki, T | 1 |
| Tsuruo, T | 1 |
| Nakanishi, O | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft Tissue Sarcoma After Pre-treatment Failure: an Open-label, Multicenter Phase II Study[NCT01136499] | Phase 2 | 53 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| A Phase I Study of Entinostat in Combination With Enzalutamide for Treatment of Patients With Castration-Resistant Prostate Cancer[NCT03829930] | Phase 1 | 6 participants (Actual) | Interventional | 2019-05-01 | Terminated (stopped due to Sponsor discontinued the drug) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 other studies available for entinostat and Cancer of Ovary
| Article | Year |
|---|---|
Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; Benzamides; Carcinoma, Squamous Cell; Cell Prol | 2019 |
Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bi | 2021 |
Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; BRCA1 Protein; Carcinoma, Ovari | 2021 |
Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Benzamides; Cell Line, Tumor; Disease Models, | 2017 |
The antitumor effects of entinostat in ovarian cancer require adaptive immunity.
Topics: Adaptive Immunity; Animals; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; | 2018 |
Entinostat finds a path: A new study elucidates effects of the histone deacetylase inhibitor on the immune system.
Topics: Adaptive Immunity; Benzamides; Female; Histone Deacetylase Inhibitors; Humans; Immune System; Ovaria | 2018 |
Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell L | 2019 |
Bioinformatics analysis reveals potential candidate drugs for psychological stress in ovarian cancer.
Topics: Benzamides; Computational Biology; Diphenylacetic Acids; Female; Humans; Oligonucleotide Array Seque | 2012 |
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
Topics: Animals; Antineoplastic Agents; Benzamides; Butyrates; Cell Cycle; Cell Survival; Colonic Neoplasms; | 1999 |
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
Topics: Animals; Antineoplastic Agents; Benzamides; Butyrates; Cell Cycle; Cell Survival; Colonic Neoplasms; | 1999 |
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
Topics: Animals; Antineoplastic Agents; Benzamides; Butyrates; Cell Cycle; Cell Survival; Colonic Neoplasms; | 1999 |
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
Topics: Animals; Antineoplastic Agents; Benzamides; Butyrates; Cell Cycle; Cell Survival; Colonic Neoplasms; | 1999 |